From Ipex to foxp3: A new contribution of pediatrics to the understanding of the immune system;De l'Ipex à foxp3 : une nouvelle contribution de la pédiatrie à la compréhension du système immunitaire

Archives de Pediatrie

Volumn 15, Issue 1, 2008, Pages 55-63

  Marabelle, A ^a,d   Meyer, M ^b   Demeocq, F ^b,c   Lachaux, A ^e,f  

^a CENTRE LÉON BÉRARD   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d UNIVERSITÉ DE LYON   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

AUTOIMMUNE DISEASE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL THERAPY; CORRELATION ANALYSIS; DIARRHEA; ENTEROPATHY; FATALITY; GENE FUNCTION; GENE MUTATION; GENETIC LINKAGE; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; IMMUNE SYSTEM; IPEX SYNDROME; LYMPHOCYTE SUBPOPULATION; PATHOPHYSIOLOGY; PHENOTYPE; REGULATORY T LYMPHOCYTE; SHORT SURVEY;

ANTIGENS, CD; AUTOIMMUNE DISEASES; CHROMOSOMES, HUMAN, X; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INFANT, NEWBORN; T-LYMPHOCYTES, REGULATORY;

EID: 38349195410     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2007.10.005     Document Type: Short Survey

References (49)

1. Powell B.R., Buist N.R., and Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr 100 (1982) 731-737
2. Godfrey V., Wilkinson J., and Russell L. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol 138 (1991) 1379-1387
3. Suri-Payer E., Amar A.Z., Thornton A.M., et al. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160 (1998) 1212-1218
4. Moller G. Do suppressor T cells exist?. Scand J Immunol 27 (1988) 247-250
5. Lachaux A., Bouvier R., Cozzani E., et al. Familial autoimmune enteropathy with circulating anti-bullous pemphigoid antibodies and chronic autoimmune hepatitis. J Pediatr 125 (1994) 858-862
6. Lyon M.F., Peters J., Glenister P.H., et al. The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. Proc Natl Acad Sci USA 87 (1990) 2433-2437
7. Bennett C.L., Yoshioka R., Kiyosawa H., et al. X-Linked syndrome of polyendocrinopathy, immune dysfunction, and diarrhea maps to Xp11.23-Xq13.3. Am J Hum Genet 66 (2000) 461-468
8. Ferguson P.J., Blanton S.H., Saulsbury F.T., et al. Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. Am J Med Genet 90 (2000) 390-397
9. Brunkow M.E., Jeffery E.W., Hjerrild K.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27 (2001) 68-73
10. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (Ipex) is caused by mutations of FOXP3. Nat Genet 27 (2001) 20-21
11. Wildin R.S., Ramsdell F., Peake J., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27 (2001) 18-20
12. Chatila T.A., Blaeser F., Ho N., et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 106 (2000) R75-R81
13. Grant C., Oh U., Fugo K., et al. Foxp3 represses retroviral transcription by targeting both NF-&kacute;B and CREB pathways. PLoS Pathog 2 (2006) e33
14. Khattri R., Kasprowicz D., Cox T., et al. The amount of scurfin protein determines peripheral T cell number and responsiveness. J Immunol 167 (2001) 6312-6320
15. Schubert L.A., Jeffery E., Zhang Y., et al. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 276 (2001) 37672-37679
16. Lopes J.E., Torgerson T.R., Schubert L.A., et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. J Immunol 177 (2006) 3133-3142
17. Chatila T.A. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116 (2005) 949-959 quiz 60
18. De Benedetti F., Insalaco A., Diamanti A., et al. Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome. Clin Gastroenterol Hepatol 4 (2006) 653-659
19. Bennett C.L., Brunkow M.E., Ramsdell F., et al. A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA→AAUGAA) leads to the Ipex syndrome. Immunogenetics 53 (2001) 435-439
20. Banerjee-Basu S., and Baxevanis A.D. Structural analysis of disease-causing mutations in the P-subfamily of forkhead transcription factors. Proteins 54 (2004) 639-647
21. Godfrey V.L., Wilkinson J.E., Rinchik E.M., et al. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci USA 88 (1991) 5528-5532
22. Blair P.J., Bultman S.J., Haas J.C., et al. CD4+CD8- T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. J Immunol 153 (1994) 3764-3774
23. Kanangat S., Blair P., Reddy R., et al. Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. Eur J Immunol 26 (1996) 161-165
24. Clark L.B., Appleby M.W., Brunkow M.E., et al. Cellular and molecular characterization of the scurfy mouse mutant. J Immunol 162 (1999) 2546-2554
25. Takahashi T., Kuniyasu Y., Toda M., et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10 (1998) 1969-1980 10.1093/intimm/10.12.1969
26. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
27. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
28. Bacchetta R., Passerini L., Gambineri E., et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 116 (2006) 1713-1722
29. Taddio A., Faleschini E., Valencic E., et al. Medium-term survival without haematopoietic stem cell transplantation in a case of Ipex: insights into nutritional and immunosuppressive therapy. Eur J Pediatr (2007)
30. Gavin M.A., Torgerson T.R., Houston E., et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 103 (2006) 6659-6664
31. Fontenot J.D., Rasmussen J.P., Williams L.M., et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005) 329-341
32. R.Walker M., Kasprowicz D.J., Gersuk V.H., et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 112 (2003) 1437-1443 10.1172/JCI200319441
33. Mucida D., Kutchukhidze N., Erazo A., et al. Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest 115 (2005) 1923-1933
34. Heltzer M.L., Choi J.K., Ochs H.D., et al. A potential screening tool for Ipex syndrome. Pediatr Dev Pathol 10 (2007) 98-105
35. Caudy A.A., Reddy S.T., Chatila T., et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 119 (2007) 482-487
36. Gambarara M., Bracci F., Diamanti A., et al. Long-term parenteral nutrition in pediatric autoimmune enteropathies. Transplant Proc 37 (2005) 2270-2271
37. Sherman P.M., Mitchell D.J., and Cutz E. Neonatal enteropathies: defining the causes of protracted diarrhea of infancy. J Pediatr Gastroenterol Nutr 38 (2004) 16-26
38. Kobayashi I., Nakanishi M., Okano M., et al. Combination therapy with tacrolimus and betamethasone for a patient with X-linked autoimmune enteropathy. Eur J Pediatr 154 (1995) 594-595
39. Di Rocco M., and Marta R. X-linked immune dysregulation, neonatal insulin dependent diabetes, and intractable diarrhoea. Arch Dis Child Fetal Neonatal Ed 75 (1996) F144
40. Bindl L., Torgerson T., Perroni L., et al. Successful use of the new immune-suppressor sirolimus in Ipex (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr 147 (2005) 256-259
41. Coenen J.J., Koenen H.J., van Rijssen E., et al. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 107 (2006) 1018-1023
42. Battaglia M., Stabilini A., and Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105 (2005) 4743-4748
43. Tanaka H., Tsugawa K., Kudo M., et al. Low-dose cyclosporine A in a patient with X- linked immune dysregulation, polyendocrinopathy and enteropathy. Eur J Pediatr 164 (2005) 779-780
44. Baud O., Goulet O., Canioni D., et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (Ipex) by allogeneic bone marrow transplantation. N Engl J Med 344 (2001) 1758-1762
45. Filipovich A.H., Bleesing J., and Goldman F. Emerging targets for hematopoietic cell transplantation (HCT): genetic disorders of hematopoiesis and immunity. Biol Blood Marrow Transplant 13 (2006) 58-63
46. Rao A., Kamani N., Filipovich A., et al. Successful bone marrow transplantation for Ipex syndrome following reduced intensity conditioning. Blood (2006)
47. Satwani P., Harrison L., Morris E., et al. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 11 (2005) 403-422
48. Tommasini A., Ferrari S., Moratto D., et al. X-chromosome inactivation analysis in a female carrier of FOXP3 mutation. Clin Exp Immunol 130 (2002) 127-130
49. Smyk-Pearson S.K., Bakke A.C., Held P.K., et al. Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes. Clin Exp Immunol 133 (2003) 193-199